Nikhil C. Munshi, MD
Adjunct Associate Professor
Boston University School of Medicine
Dept of Medicine
Hematology & Medical Oncology

MBBS, Maharaja Sayajirao University
MD, Maharaja Sayajirao University




Dr. Nikhil Munshi received his medical degree from Maharaja Sayajirao University, followed by an internship and residency in internal medicine at Shri Sayaji General Hospital and Maharaja University in India. He then completed an oncology fellowship at Johns Hopkins Ocology Center, and an hematology/oncology fellowhip at Indiana University Medical Center. Dr. Munshi is currently professor of medicine in the Department of Medicine at Harvard Medical School, as well as an attending physician at VA Boston Healthcare System and Dana-Farber Cancer Institute.

A diplomate of American Board of Internal Medicine, Dr. Munshi is also on the Board of Directors of the International Myeloma Society. He is a member of numerous professional associations including the Indian Medical Association, Physician’s Association of India, Indian Association of Clinical Oncology, American Medical Association, American Society of Clinical Oncology, and the American Society of Hematology, among others. In addition, he is on the editorial board of Clinical Lymphoma and Myeloma and Personalized Medicine in Oncology and is an ad hoc reviewer for numerous professional journals.

Dr. Munshi’s current laboratory research and clinical activities specialize in plasma cell disorders with a focus on understanding oncogenomic changes in myeloma and developing a translational research programs in myeloma. He has also established a Myeloma Initiative at Veterans Administration Hospitals, a comprehensive program bringing together, for the first time, all major VA hospitals across the country to focus on cutting-edge joint clinical studies.

VA Boston Healthcare System






Title
Integrative Oncogenomics of Multiple Myeloma
SPORE in Multiple Myeloma
Molecular Manipulation to Enhance Anti-Myeloma Response


Yr Title Project-Sub Proj Pubs
2020 Molecular Manipulation to Enhance Anti-Myeloma Response 5I01BX001584-07 40
2020 Integrative Oncogenomics of Multiple Myeloma 5P01CA155258-09 229
2020 Core 1: Administrative and Communication Core 5P01CA155258-09-5939 229
2020 Project 4. Targeting genomic instability and evolution in myeloma 5P01CA155258-09-5947 229
2020 SPORE in Multiple Myeloma 5P50CA100707-17 422
2020 Tissue Banking Core 5P50CA100707-17-8564 422
2020 Targeting AP Nuclease, a Mediator of Genomic Instability in MM 5P50CA100707-17-8567 422
2019 ShEEP request for next generation sequencing system 1IS1BX005034-01
2019 Molecular Manipulation to Enhance Anti-Myeloma Response 5I01BX001584-06 40
2019 Integrative Oncogenomics of Multiple Myeloma 5P01CA155258-08 229
Showing 10 of 78 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Fillmore NR, La J, Szalat RE, Tuck DP, Nguyen V, Yildirim C, Do NV, Brophy MT, Munshi NC. Prevalence and outcome of COVID-19 infection in cancer patients: a national Veterans Affairs study. J Natl Cancer Inst. 2020 Oct 08.View Related Profiles. PMID: 33031532
     
  2. Cho SF, Lin L, Xing L, Li Y, Wen K, Yu T, Hsieh PA, Munshi N, Wahl J, Matthes K, Friedrich M, Arvedson T, Anderson KC, Tai YT. The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models. Blood Adv. 2020 Sep 08; 4(17):4195-4207. PMID: 32898244
     
  3. Corre J, Munshi NC, Avet-Loiseau H. Risk factors in MM: is it time for a revision? Blood. 2020 Sep 05. PMID: 33024991
     
  4. Xu Y, Fulciniti M, Samur MK, Ho M, Deng S, Liu L, Wen K, Yu T, Chyra Z, Dereibal S, Zhang L, Yao Y, Chakraborty C, Morelli E, Li N, Lopez MA, Perini T, Mu S, An G, Alonso R, Bianchi G, Tai YT, Anderson KC, Qiu L, Munshi NC. YWHAE/14-3-3e expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma. Blood. 2020 Jul 23; 136(4):468-479. PMID: 32187357
     
  5. Samur MK, Aktas Samur A, Fulciniti M, Szalat R, Han T, Shammas M, Richardson P, Magrangeas F, Minvielle S, Corre J, Moreau P, Thakurta A, Anderson KC, Parmigiani G, Avet-Loiseau H, Munshi NC. Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group. J Clin Oncol. 2020 Sep 20; 38(27):3107-3118. PMID: 32687451
     
  6. Lin L, Cho SF, Xing L, Wen K, Li Y, Yu T, Hsieh PA, Chen H, Kurtoglu M, Zhang Y, Andrew Stewart C, Munshi N, Anderson KC, Tai YT. Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma. Leukemia. 2020 Jul 06. PMID: 32632095
     
  7. Shah N, Aiello J, Avigan DE, Berdeja JG, Borrello IM, Chari A, Cohen AD, Ganapathi K, Gray L, Green D, Krishnan A, Lin Y, Manasanch E, Munshi NC, Nooka AK, Rapoport AP, Smith EL, Vij R, Dhodapkar M. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. J Immunother Cancer. 2020 Jul; 8(2). PMID: 32661116
     
  8. Bae J, Parayath N, Ma W, Amiji M, Munshi N, Anderson KC. Correction: BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications. Leukemia. 2020 Jul; 34(7):1971. PMID: 31949267
     
  9. Mouhieddine TH, Sperling AS, Redd R, Park J, Leventhal M, Gibson CJ, Manier S, Nassar AH, Capelletti M, Huynh D, Bustoros M, Sklavenitis-Pistofidis R, Tahri S, Hornburg K, Dumke H, Itani MM, Boehner CJ, Liu CJ, AlDubayan SH, Reardon B, Van Allen EM, Keats JJ, Stewart C, Mehr S, Auclair D, Schlossman RL, Munshi NC, Anderson KC, Steensma DP, Laubach JP, Richardson PG, Ritz J, Ebert BL, Soiffer RJ, Trippa L, Getz G, Neuberg DS, Ghobrial IM. Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020 06 12; 11(1):2996. PMID: 32533060
     
  10. Bustoros M, Sklavenitis-Pistofidis R, Park J, Redd R, Zhitomirsky B, Dunford AJ, Salem K, Tai YT, Anand S, Mouhieddine TH, Chavda SJ, Boehner C, Elagina L, Neuse CJ, Cha J, Rahmat M, Taylor-Weiner A, Van Allen E, Kumar S, Kastritis E, Leshchiner I, Morgan EA, Laubach J, Casneuf T, Richardson P, Munshi NC, Anderson KC, Trippa L, Aguet F, Stewart C, Dimopoulos MA, Yong K, Bergsagel PL, Manier S, Getz G, Ghobrial IM. Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. J Clin Oncol. 2020 Jul 20; 38(21):2380-2389. PMID: 32442065
     
Showing 10 of 476 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 476 publications over 25 distinct years, with a maximum of 29 publications in 2015

YearPublications
19961
19975
19987
199913
20006
200114
200226
200325
200416
200516
200619
200720
200820
200926
201021
201125
201222
201328
201425
201529
201623
201725
201827
201919
202018

Contact for Mentoring:

Munshi's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department